- Home
- RF vs WAT Comparison
RF vs WAT Comparison
Compare RF & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RF | WAT |
|---|---|---|
| Founded | 1970 | 1958 |
| Country | United States | United States |
| Employees | N/A | 7600 |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 22.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | RF | WAT |
|---|---|---|
| Price | $27.60 | $376.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | $27.36 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 12.0M | 552.9K |
| Earning Date | 01-16-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 27.93 | 3.82 |
| EPS | 2.27 | ★ 10.88 |
| Revenue | ★ $6,945,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | $18.34 | $7.96 |
| Revenue Next Year | $4.06 | $6.32 |
| P/E Ratio | ★ $12.12 | $34.80 |
| Revenue Growth | 5.90 | ★ 6.90 |
| 52 Week Low | $17.74 | $275.05 |
| 52 Week High | $27.98 | $423.56 |
Technical Indicators
Market Signals| Indicator | RF | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 44.27 |
| Support Level | $27.21 | $372.93 |
| Resistance Level | $27.98 | $397.55 |
| Average True Range (ATR) | 0.52 | 9.38 |
| MACD | 0.16 | -4.13 |
| Stochastic Oscillator | 87.58 | 10.06 |
Price Performance
Historical ComparisonAbout RF Regions Financial Corporation
Regions Financial is a regional bank based in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.